MLL-rearranged infant ALL versus pediatric precursor B-ALL (HU95A): dataset validation. Heatmaps separating our MLL-rearranged infant ALL (n = 59) from pediatric precursor B-ALL (n = 16) samples based on the MLL-rearranged ALL specific gene expression signatures (obtained on HU95A microarrays) published by Armstrong et al¹²  (A) and Yeoh et al²  (C). Columns represent patient samples, and rows represent the gene names corresponding to the probe sets. Normalized gene expression is depicted in red (high expression) or blue (low expression). (B,D) PCA for both signatures, respectively. Red dots indicate MLL-rearranged infant ALL samples (including t(4;11) (n = 29), t(11;19) (n = 22), and t(9;11)-positive (n = 8) cases), and blue dots represent pediatric precursor B-ALL cases (n = 16). Patient characteristics and detailed gene descriptions are listed in supplemental Tables 1, 3, and 4.